Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis

Author:Pardo, Gabriel   Hauser, Stephen   Bar-Or, Amit   Gold, Ralf   Montalban, Xavier   Cohen, Jeffrey   Robertson, Derrick   Hersh, Carrie   Naismith, Robert   Deiva, Kumaran   Bhatt, Alit   Fu, Haoyi   Boer, Ibolya   Meuth, Sven   Cross, Anne   Gärtner, Jutta   Kappos, Ludwig   

Session Name:S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making  

Topic:Multiple Sclerosis  

Program Number:S31.003  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma, USA, Oklahoma City, OK  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA, San Francisco, CA  Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  Department of Neurology, Katholisches Klinikum Bochum, Ruhr-Universität Bochum, Bochum, Germany, Bochum, Germany  Department of Neurology Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, Florida, USA, Tampa, FL  Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, United States, Las Vegas, NV  Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA, Saint Louis, MO  Department of Pediatric Neurology, University Hospitals Paris Saclay, Hôpital Bicêtre, National Reference Center for Rare Inflammatory Brain and Spinal Diseases, Le Kremlin Bicêtre, France, Le Kremlin Bicêtre, France  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Duesseldorf, Germany  Department of Neurology, Section of Neuroimmunology, Washington University School of Medicine, Saint Louis, Missouri, USA, Clayton, MO  Department of Paediatrics and Adolescent Medicine, Division of Paediatric Neurology, University Medical Centre Göttingen, Georg August University Göttingen, Göttingen, Germany, Göttingen, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Organs, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland